IRIS
BIANCO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.489
EU - Europa 1.853
AS - Asia 409
AF - Africa 74
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 4.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.440
IT - Italia 952
CN - Cina 299
UA - Ucraina 206
NL - Olanda 166
IE - Irlanda 130
DE - Germania 117
FI - Finlandia 117
CI - Costa d'Avorio 73
FR - Francia 51
SE - Svezia 50
CA - Canada 47
GB - Regno Unito 39
IN - India 39
VN - Vietnam 30
PK - Pakistan 20
BE - Belgio 6
IR - Iran 5
SG - Singapore 5
BG - Bulgaria 4
ES - Italia 3
GR - Grecia 3
HK - Hong Kong 3
MY - Malesia 3
SI - Slovenia 3
AU - Australia 2
CL - Cile 2
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
AT - Austria 1
BD - Bangladesh 1
BZ - Belize 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
JP - Giappone 1
KR - Corea 1
MK - Macedonia 1
MX - Messico 1
PL - Polonia 1
RS - Serbia 1
RU - Federazione Russa 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 4.833
Salva come PNG Salva come JPEG
Città #
Chandler 484
Jacksonville 234
Napoli 189
Amsterdam 164
Millbury 153
Naples 148
Ashburn 132
Princeton 115
Beijing 83
Nanjing 72
Boston 64
Wilmington 59
Woodbridge 54
Ottawa 46
Des Moines 43
Nanchang 35
Rome 33
Dong Ket 28
Pune 25
Hebei 24
Houston 24
Hicksville 23
Shenyang 23
Caserta 20
Lawrence 19
Norwalk 19
Ann Arbor 18
Boardman 18
Milan 17
Jiaxing 15
Redwood City 14
Islamabad 13
Tianjin 13
Kronberg 12
San Mateo 12
Seattle 11
Changsha 10
Falls Church 8
Modica 8
Salerno 8
Villarosa 8
Washington 8
Casoria 7
Formia 7
Palma Campania 7
Rozzano 7
Shanghai 7
Indiana 6
Angri 5
Lahore 5
Leawood 5
Nürnberg 5
Turin 5
Augusta 4
Florence 4
Fucecchio 4
Kolkata 4
Los Angeles 4
Menfi 4
Siena 4
Sofia 4
Villaricca 4
Ardabil 3
Caivano 3
Casagiove 3
Castel San Giovanni 3
Dearborn 3
Hong Kong 3
Lanzhou 3
Latina 3
Menlo Park 3
Monte Di Procida 3
Pizzo 3
Pozzuoli 3
Salt Lake City 3
Serravalle Scrivia 3
Veroli 3
Yellow Springs 3
Andria 2
Aversa 2
Bari 2
Bologna 2
Brussels 2
Castellammare Di Stabia 2
Catania 2
Changchun 2
Dublin 2
Duncan 2
Edegem 2
Fairfield 2
Frattamaggiore 2
Grumo Nevano 2
Hangzhou 2
Hanoi 2
Harbin 2
Krefeld 2
Kuala Lumpur 2
Kunming 2
La Canada Flintridge 2
Lecce 2
Totale 2.700
Salva come PNG Salva come JPEG
Nome #
null 223
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 89
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 85
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 85
Studio dei meccanismi autocrini e paracrini di attivazione di Hedgehog in modelli tumorali umani. 73
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents 71
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 68
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 61
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 61
AXL is an oncotarget in human colorectal cancer 57
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 57
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 53
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 50
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase III trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small cell lung cancer 49
ANTITUMOR ACTIVITY OF ZD6474, A VEGFR-2 AND EGFR SMALL MOLECULE TYROSINE KINASE INHIBITOR, IN COMBINATION WITH SC-236, A CYCLOOXYGENASE-2 INHIBITOR. 49
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 49
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 49
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 48
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 46
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 46
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 46
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 45
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 45
From biology to therapy: Improvements of therapeutic options in Lung cancer 45
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 44
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 44
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 44
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 43
Combination of biological therapies in non-small cell lung cancer. 43
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 43
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 42
Mechanisms of resistance to mTOR inhibitors 42
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 41
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 41
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 41
COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. 41
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 41
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 41
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 41
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 41
MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. 40
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 40
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 40
ANTITUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. 39
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 39
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 38
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 37
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. 37
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 37
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 37
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 37
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 36
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 36
Approaches for targeting cancer stem cells drug resistance 36
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 36
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 35
Mechanisms of lapatinib resistance in HER2-driven breast cancer 35
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 35
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 34
INTRINSIC AND ACQUIRED RESISTANCE TO EGFR INHIBITORS IN HUMAN CANCER THERAPY. 34
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. 33
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 33
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 33
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors 33
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 32
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 32
Oxidative stress mediates the antiproliferative effects of nelfinavir in breast cancer cells 32
CHEMOSENSITIZATION BY ANTISENSE OLIGONUCLEOTIDES TARGETING MDM2. 31
Key cancer cell signal transduction pathways as therapeutic targets. 31
The mechanisms of resistance to EGFR inhibitors. 31
Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. 31
Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. 31
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 31
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 30
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 30
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 30
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 30
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 30
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 30
MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1 30
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 30
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 29
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 29
Preliminary analysis of chemotheraphy-induced cardiotoxicity in breast cancer patients trated with Amifostine. 29
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 29
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 28
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 28
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 28
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 27
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 27
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 27
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 26
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 26
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 25
Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozime of cyclic AMP-dependent protein kinase. 25
Correlation between bevacizumab-related hypertension and response in mCRC patients 25
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 25
Integr(at)in(g) EGFR therapy in HNSCC 25
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. 24
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 24
Totale 4.121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.731
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.731
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201928 0 0 0 0 0 0 0 0 0 0 13 15
2019/2020648 199 5 64 21 81 26 12 10 4 50 71 105
2020/2021647 7 45 60 50 80 84 69 11 89 29 79 44
2021/2022871 16 1 11 25 12 25 11 29 154 73 206 308
2022/20231.270 143 103 46 87 143 148 7 121 198 179 57 38
2023/2024734 31 130 127 91 37 97 25 105 16 21 54 0
Totale 5.084